{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,8,2]],"date-time":"2025-08-02T18:58:18Z","timestamp":1754161098152,"version":"3.41.2"},"reference-count":40,"publisher":"Danish Medical Association","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Dan Med J"],"abstract":"<jats:p>With the introduction of specific or unspecific biomarkers, the diagnosis of dementia disorders has changed from a purely clinical to a biological construct. This review presents biomarkers for the most common neurodegenerative disorders. Specific biomarkers for misfolded proteins have been developed for Alzheimer\u2019s disease and dementia with Lewy bodies. Unspecific biomarkers for neurodegeneration, synaptic dysfunction and neuroinflammation may also be helpful in diagnosing or staging dementia disorders.<\/jats:p>","DOI":"10.61409\/a09240634","type":"journal-article","created":{"date-parts":[[2025,2,28]],"date-time":"2025-02-28T02:58:19Z","timestamp":1740711499000},"page":"1-8","source":"Crossref","is-referenced-by-count":0,"title":["Biomarkers in dementia disorders \u2013 a narrative review"],"prefix":"10.61409","author":[{"given":"Steen Gregers","family":"Hasselbalch","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"40208","published-online":{"date-parts":[[2025,3,1]]},"reference":[{"key":"ref0","unstructured":"Alzheimer Europe. Dementia in Europe Yearbook 2019: Estimating the prevalence of dementia in Europe. 2019. https:\/\/www.alzheimer-europe.org\/sites\/default\/files\/alzheimer_europe_dementia_in_europe_yearbook_2019.pdf (12 Feb 2025)"},{"key":"ref1","doi-asserted-by":"publisher","unstructured":"Taudorf L, N\u00f8rgaard A, Islamoska S, et al. Declining incidence of dementia: A national registry-based study over 20 years. Alzheimers Dement. 2019;15(11):1383-91. https:\/\/doi.org\/10.1016\/j.jalz.2019.07.006","DOI":"10.1016\/j.jalz.2019.07.006"},{"key":"ref2","doi-asserted-by":"publisher","unstructured":"Bloudek LM, Spackman DE, Blankenburg M, et al. Review and meta-analysis of biomarkers and diagnostic imaging in Alzheimer's disease. J Alzheimers Dis. 2011;26(4):627-45. https:\/\/doi.org\/10.3233\/JAD-2011-110458","DOI":"10.3233\/JAD-2011-110458"},{"key":"ref3","unstructured":"World Health Organization (WHO). International Classification of Diseases (ICD-11). Eleventh Revision. 2019. https:\/\/www.who.int\/standards\/classifications\/classification-of-diseases (12 Feb 2025)"},{"key":"ref4","doi-asserted-by":"publisher","unstructured":"American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders, 5th Edition. 2013. https:\/\/doi.org\/10.1176\/appi.books.9780890425596","DOI":"10.1176\/appi.books.9780890425596"},{"key":"ref5","doi-asserted-by":"publisher","unstructured":"Selkoe DJ, Hardy J. The amyloid hypothesis of Alzheimer's disease at 25 years. EMBO Mol Med. 2016;8(6):595-608. https:\/\/doi.org\/10.15252\/emmm.201606210","DOI":"10.15252\/emmm.201606210"},{"key":"ref6","doi-asserted-by":"publisher","unstructured":"Musiek ES, Holtzman DM. Three dimensions of the amyloid hypothesis: time, space and \"wingmen\". Nat Neurosci 2015;18:800-6. https:\/\/doi.org\/10.1038\/nn.4018","DOI":"10.1038\/nn.4018"},{"key":"ref7","doi-asserted-by":"publisher","unstructured":"Jansen WJ, Ossenkoppele R, Knol DL, et al. Prevalence of cerebral amyloid pathology in persons without dementia: a meta-analysis. JAMA 2015;313:1924-38. https:\/\/doi.org\/10.1001\/jama.2015.4668","DOI":"10.1001\/jama.2015.4668"},{"key":"ref8","doi-asserted-by":"publisher","unstructured":"Bateman RJ, Xiong C, Benzinger TL, et al. Clinical and biomarker changes in dominantly inherited Alzheimer's disease [published correction appears in N Engl J Med. 2012 Aug 23;367(8):780]. N Engl J Med. 2012;367(9):795-804. https:\/\/doi.org\/10.1056\/NEJMoa1202753","DOI":"10.1056\/NEJMoa1202753"},{"key":"ref9","doi-asserted-by":"publisher","unstructured":"Mil\u00e0-Alom\u00e0 M, Ashton NJ, Shekari M, et al. Plasma p-tau231 and p-tau217 as state markers of amyloid-\u03b2 pathology in preclinical Alzheimer's disease [published correction appears in Nat Med. 2022 Sep;28(9):1965. doi: 10.1038\/s41591-022-02037-1.]. Nat Med. 2022;28(9):1797-1801. https:\/\/doi.org\/10.1038\/s41591-022-01925-w","DOI":"10.1038\/s41591-022-01925-w"},{"key":"ref10","doi-asserted-by":"publisher","unstructured":"Burton EJ, Barber R, Mukaetova-Ladinska EB, et al. Medial temporal lobe atrophy on MRI differentiates Alzheimer's disease from dementia with Lewy bodies and vascular cognitive impairment: a prospective study with pathological verification of diagnosis. Brain. 2009;132(Pt 1):195-203. https:\/\/doi.org\/10.1093\/brain\/awn298","DOI":"10.1093\/brain\/awn298"},{"key":"ref11","doi-asserted-by":"publisher","unstructured":"Simr\u00e9n J, Elmgren A, Blennow K, Zetterberg H. Fluid biomarkers in Alzheimer's disease. Adv Clin Chem. 2023;112:249-81. https:\/\/doi.org\/10.1016\/bs.acc.2022.09.006","DOI":"10.1016\/bs.acc.2022.09.006"},{"key":"ref12","doi-asserted-by":"publisher","unstructured":"Colom-Cadena M, Spires-Jones T, Zetterberg H, et al. The clinical promise of biomarkers of synapse damage or loss in Alzheimer's disease. Alzheimers Res Ther. 2020;12(1):21. https:\/\/doi.org\/10.1186\/s13195-020-00588-4","DOI":"10.1186\/s13195-020-00588-4"},{"key":"ref13","doi-asserted-by":"publisher","unstructured":"McKhann GM, Knopman DS, Chertkow H, et al. The diagnosis of dementia due to Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimers Dement. 2011;7(3):263-9. https:\/\/doi.org\/10.1016\/j.jalz.2011.03.005","DOI":"10.1016\/j.jalz.2011.03.005"},{"key":"ref14","doi-asserted-by":"publisher","unstructured":"Jack CR Jr, Bennett DA, Blennow K, et al. NIA-AA Research Framework: Toward a biological definition of Alzheimer's disease. Alzheimers Dement. 2018;14(4):535-62. https:\/\/doi.org\/10.1016\/j.jalz.2018.02.018","DOI":"10.1016\/j.jalz.2018.02.018"},{"key":"ref15","doi-asserted-by":"publisher","unstructured":"Jack CR, Andrews JS, Beach TG, et al. Revised criteria for diagnosis and staging of Alzheimer's disease: Alzheimer's Association Workgroup. Alzheimer's & Dementia 2024;20:5143-69. https:\/\/doi.org\/10.1002\/alz.13859","DOI":"10.1002\/alz.13859"},{"key":"ref16","doi-asserted-by":"publisher","unstructured":"Doecke JD, Ward L, Burnham SC, et al. Elecsys CSF biomarker immunoassays demonstrate concordance with amyloid-PET imaging. Alzheimers Res Ther.2020;12(1):36. https:\/\/doi.org\/10.1186\/s13195-020-00595-5","DOI":"10.1186\/s13195-020-00595-5"},{"key":"ref17","doi-asserted-by":"publisher","unstructured":"Mattsson-Carlgren N, Grinberg LT, Boxer A, et al. Cerebrospinal Fluid Biomarkers in Autopsy-Confirmed Alzheimer Disease and Frontotemporal Lobar Degeneration. Neurology 2022;98. https:\/\/doi.org\/10.1212\/WNL.0000000000200040","DOI":"10.1212\/WNL.0000000000200040"},{"key":"ref18","doi-asserted-by":"publisher","unstructured":"Engelborghs S, De Vreese K, Van de Casteele T, et al. Diagnostic performance of a CSF-biomarker panel in autopsy-confirmed dementia. Neurobiol Aging 2008;29:1143-59. https:\/\/doi.org\/10.1016\/j.neurobiolaging.2007.02.016","DOI":"10.1016\/j.neurobiolaging.2007.02.016"},{"key":"ref19","doi-asserted-by":"publisher","unstructured":"Barth\u00e9lemy NR, Salvad\u00f3 G, Schindler SE, et al. Highly accurate blood test for Alzheimer's disease is similar or superior to clinical cerebrospinal fluid tests. Nat Med 2024;30:1085-95. https:\/\/doi.org\/10.1038\/s41591-024-02869-z","DOI":"10.1038\/s41591-024-02869-z"},{"key":"ref20","doi-asserted-by":"publisher","unstructured":"Groot C, Villeneuve S, Smith R, et al. Tau PET Imaging in Neurodegenerative Disorders. J Nucl Med. 2022;63(Suppl 1):20S-26S. https:\/\/doi.org\/10.2967\/jnumed.121.263196","DOI":"10.2967\/jnumed.121.263196"},{"key":"ref21","doi-asserted-by":"publisher","unstructured":"Salvad\u00f3 G, Larsson V, Cody KA, et al. Optimal combinations of CSF biomarkers for predicting cognitive decline and clinical conversion in cognitively unimpaired participants and mild cognitive impairment patients: A multi-cohort study. Alzheimers Dement. 2023;19(7):2943-55. https:\/\/doi.org\/10.1002\/alz.12907","DOI":"10.1002\/alz.12907"},{"key":"ref22","doi-asserted-by":"publisher","unstructured":"Saloner R, VandeVrede L, Asken BM, et al. Plasma phosphorylated tau-217 exhibits sex-specific prognostication of cognitive decline and brain atrophy in cognitively unimpaired adults. Alzheimers Dement. 2024;20(1):376-87. https:\/\/doi.org\/10.1002\/alz.13454","DOI":"10.1002\/alz.13454"},{"key":"ref23","doi-asserted-by":"publisher","unstructured":"Therriault J, Pascoal TA, Lussier FZ, et al. Biomarker modeling of Alzheimer's disease using PET-based Braak staging. Nat Aging 2022;2:526-35. https:\/\/doi.org\/10.1038\/s43587-022-00204-0","DOI":"10.1038\/s43587-022-00204-0"},{"key":"ref24","doi-asserted-by":"publisher","unstructured":"Arnold MR, Coughlin DG, Brumbach BH, et al. \u03b1\u2010Synuclein seed amplification in CSF and brain from patients with different brain distributions of pathological \u03b1\u2010synuclein in the context of co\u2010pathology and non\u2010LBD diagnoses. Ann Neurol 2022;92:650-62. https:\/\/doi.org\/10.1002\/ana.26453","DOI":"10.1002\/ana.26453"},{"key":"ref25","doi-asserted-by":"publisher","unstructured":"Simuni T, Chahine LM, Poston K, et al. A biological definition of neuronal \u03b1-synuclein disease: towards an integrated staging system for research. Lancet Neurol 2024;23:178-90. https:\/\/doi.org\/10.1016\/S1474-4422(23)00405-2","DOI":"10.1016\/S1474-4422(23)00405-2"},{"key":"ref26","doi-asserted-by":"publisher","unstructured":"Gramkow MH, Gjerum L, Koikkalainen J, et al. Prognostic value of complementary biomarkers of neurodegeneration in a mixed memory clinic cohort. PeerJ 2020;8:e9498. https:\/\/doi.org\/10.7717\/peerj.9498","DOI":"10.7717\/peerj.9498"},{"key":"ref27","doi-asserted-by":"publisher","unstructured":"Gjerum L, Frederiksen KS, Henriksen OM, et al. Evaluating 2-[18F]FDG-PET in differential diagnosis of dementia using a data-driven decision model. Neuroimage Clin 2020;27:102267. https:\/\/doi.org\/10.1016\/j.nicl.2020.102267","DOI":"10.1016\/j.nicl.2020.102267"},{"key":"ref28","doi-asserted-by":"publisher","unstructured":"Minoshima S, Cross D, Thientunyakit T, et al. 18 F-FDG PET Imaging in Neurodegenerative Dementing Disorders: Insights into Subtype Classification, Emerging Disease Categories, and Mixed Dementia with Copathologies. J Nuclear Med 2022;63:2S-12S. https:\/\/doi.org\/10.2967\/jnumed.121.263194","DOI":"10.2967\/jnumed.121.263194"},{"key":"ref29","doi-asserted-by":"publisher","unstructured":"Simonsen AH, Gleerup HS, Musaeus CS, et al. Neurofilament light chain levels in serum among a large mixed memory clinic cohort: Confounders and diagnostic usefulness. Alzheimer's & Dementia: Diagnosis, Assessment & Disease Monitoring 2023;15. https:\/\/doi.org\/10.1002\/dad2.12512","DOI":"10.1002\/dad2.12512"},{"key":"ref30","doi-asserted-by":"publisher","unstructured":"Delaby C, Alcolea D, Carmona-Iragui M, et al. Differential levels of neurofilament light protein in cerebrospinal fluid in patients with a wide range of neurodegenerative disorders. Sci Rep 2020;10:9161. https:\/\/doi.org\/10.1038\/s41598-020-66090-x","DOI":"10.1038\/s41598-020-66090-x"},{"key":"ref31","doi-asserted-by":"publisher","unstructured":"Duering M, Konieczny MJ, Tiedt S, et al. Serum Neurofilament light chain levels are related to small vessel disease burden. J Stroke 2018;20:228-38. https:\/\/doi.org\/10.5853\/jos.2017.02565","DOI":"10.5853\/jos.2017.02565"},{"key":"ref32","doi-asserted-by":"publisher","unstructured":"Holmegaard L, Jensen C, Pedersen A, et al. Circulating levels of neurofilament light chain as a biomarker of infarct and white matter hyperintensity volumes after ischemic stroke. Sci Rep 2024;14:16180. https:\/\/doi.org\/10.1038\/s41598-024-67232-1","DOI":"10.1038\/s41598-024-67232-1"},{"key":"ref33","doi-asserted-by":"publisher","unstructured":"Andersson E, \u00d6st M, Dalla K, et al. Acute-phase neurofilament light and glial fibrillary acidic proteins in cerebrospinal fluid predict long-term outcome after severe traumatic brain injury. Neurocrit Care 2024; https:\/\/doi.org\/10.1007\/s12028-024-01998-0","DOI":"10.1007\/s12028-024-01998-0"},{"key":"ref34","doi-asserted-by":"publisher","unstructured":"Cousins KAQ, Shaw LM, Chen-Plotkin A, et al. Distinguishing frontotemporal lobar degeneration Tau from TDP-43 using plasma biomarkers. JAMA Neurol 2022;79:1155-64. https:\/\/doi.org\/10.1001\/jamaneurol.2022.3265","DOI":"10.1001\/jamaneurol.2022.3265"},{"key":"ref35","doi-asserted-by":"publisher","unstructured":"Pereira JB, Janelidze S, Smith R, et al. Plasma GFAP is an early marker of amyloid-\u03b2 but not tau pathology in Alzheimer's disease. Brain 2021;144:3505-16. https:\/\/doi.org\/10.1093\/brain\/awab223","DOI":"10.1093\/brain\/awab223"},{"key":"ref36","doi-asserted-by":"publisher","unstructured":"Benedet AL, Mil\u00e0-Alom\u00e0 M, Vrillon A, et al. Differences between plasma and cerebrospinal fluid glial fibrillary acidic protein levels across the Alzheimer disease continuum. JAMA Neurol 2021;78:1471. https:\/\/doi.org\/10.1001\/jamaneurol.2021.3671","DOI":"10.1001\/jamaneurol.2021.3671"},{"key":"ref37","doi-asserted-by":"publisher","unstructured":"Biel D, Su\u00e1rez\u2010Calvet M, Hager P, et al. sTREM2 is associated with amyloid\u2010related p\u2010tau increases and glucose hypermetabolism in Alzheimer's disease. EMBO Mol Med 2023;15. https:\/\/doi.org\/10.15252\/emmm.202216987","DOI":"10.15252\/emmm.202216987"},{"key":"ref38","doi-asserted-by":"publisher","unstructured":"Bavarsad MS, Grinberg LT. SV2A PET imaging in human neurodegenerative diseases. Front Aging Neurosci 2024;16. https:\/\/doi.org\/10.3389\/fnagi.2024.1380561","DOI":"10.3389\/fnagi.2024.1380561"},{"key":"ref39","doi-asserted-by":"publisher","unstructured":"Willemse EAJ, Sieben A, Somers C, et al. Neurogranin as biomarker in CSF is non-specific to Alzheimer's disease dementia. Neurobiol Aging 2021;108:99-109. https:\/\/doi.org\/10.1016\/j.neurobiolaging.2021.08.002","DOI":"10.1016\/j.neurobiolaging.2021.08.002"}],"container-title":["Danish Medical Journal"],"original-title":[],"deposited":{"date-parts":[[2025,7,28]],"date-time":"2025-07-28T14:00:21Z","timestamp":1753711221000},"score":1,"resource":{"primary":{"URL":"https:\/\/ugeskriftet.dk\/dmj\/A09240634"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3,1]]},"references-count":40,"URL":"https:\/\/doi.org\/10.61409\/a09240634","relation":{},"ISSN":["2245-1919"],"issn-type":[{"type":"electronic","value":"2245-1919"}],"subject":[],"published":{"date-parts":[[2025,3,1]]}}}